AHA 2023 | SELECT Trial: Semaglutide in Patients Without Diabetes

Given the obesity pandemic projected for the year 2035, it is imperative to address this disease as a priority, through well-known hygienic-dietary measures and the use of drugs that have shown promising results. Obesity has been identified as an independent cardiovascular risk factor, even after modifying risk factors associated with diabetes.

AHA 2023 | ORBITA-2: Angioplastia coronaria vs placebo en angina estable para la reducción de síntomas

Semaglutide, a GLP-1 agonist, has shown a significant reduction in major adverse cardiovascular events (MACE) in overweight/obese patients with diabetes. This type of agents affects a wide range of metabolic pathways related to glucose metabolism, energy homeostasis, and some triggers of inflammation, suggesting improvements in cardiovascular outcomes through multiple factors.

The SELECT study aimed to assess whether adding Semaglutide to standard treatment could outperform a placebo in reducing MACE in overweight or obese patients with pre-existing cardiovascular disease and without diabetes. It was a multicenter, randomized, superiority study conducted in 41 countries and included patients over 45 years old with a body mass index (BMI) of 27 or higher and a history of cardiovascular disease (myocardial infarction, stroke, or peripheral arterial disease).

Randomization was 1:1 between patients eligible for the administration of the target dose of subcutaneous Semaglutide 2.4 mg once a week and those who received a placebo. The primary efficacy endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.

Read also: AHA 2023 | Use of Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.

Of the 17,604 patients analyzed, 8803 were randomized to receive Semaglutide and 8801 to receive a placebo. The average age was 61.6 years, and 72% of the population was composed by men. The average BMI was 33 and the average glycated hemoglobin was 5.8. The primary endpoint occurred in 6.5% of patients receiving Semaglutide and 8% of the placebo group (hazard ratio [HR]: 0.80, 95% confidence interval [CI]: 0.72-0.90; P<0.001). Cardiovascular death occurred in 2.5% of the Semaglutide group and 3% of the placebo group (HR: 0.85, 95% CI: 0.71-1.01; p = 0.07), while the HR for the composite related to heart failure was 0.82 (95% CI: 0.71-0.96).

There was a 16.6% incidence of adverse effects leading to the discontinuation of Semaglutide, mainly related to gastrointestinal events (10%).

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Presented by Michael Lincoff in AHA 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Direct Oral Anticoagulants for Ventricular Thrombus After STEMI

While the incidence of intracavitary thrombi after acute myocardial infarction (AMI) has decreased thanks to optimized primary angioplasty times, some studies report rates of...

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Acute Coronary Syndrome with Multivessel Disease: Best Revascularization Strategy

The gold standard treatment for acute coronary syndrome (ACS), especially acute myocardial infarction (AMI) is primary angioplasty (PCI). However, 40 to 70% of ACS...

Improved Ejection Fraction in Chronic Total Occlusion?

Chronic total occlusions (CTO) represent a significant challenge in the current clinical practice, seeing as CTO percutaneous coronary intervention (PCI) is complex and involves...

TAVR and Surgical Bailout: Temporal Trends and Clinical Implications

The evolution of transcatheter aortic valve replacement (TAVR), both regarding its planning and execution, has resulted in minimally invasive interventions with high safety levels....